Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $5.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jason McCarthy has given his Buy rating due to a combination of factors related to Actinium Pharmaceuticals’ promising developments. Actinium’s ATNM-400, a targeted radiotherapy utilizing Actinium-225, has shown significant anti-tumor activity across various cancer types, including breast, lung, and prostate cancers. This includes effectiveness in treatment-resistant models, which positions Actinium as a leader in the radiopharmaceutical and antibody-drug conjugate sectors.
Furthermore, the company is well-capitalized with a strong financial position, having $53.4 million in cash at the end of the third quarter of 2025, providing a solid runway for continued development. The undisclosed target of ATNM-400, which is associated with tumor progression and resistance, adds a layer of intrigue and potential for future growth. These factors collectively underpin McCarthy’s optimistic outlook and Buy rating for Actinium Pharmaceuticals.
McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Plus Therapeutics, and SCYNEXIS. According to TipRanks, McCarthy has an average return of -7.8% and a 37.42% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.